Literature DB >> 6324671

Ketoconazole in the prevention of experimental candidal vaginitis.

J D Sobel, G Muller.   

Abstract

The prophylactic and therapeutic activities of ketoconazole were evaluated in rats inoculated intravaginally with Candida albicans. Daily doses of 2.5 mg/kg initiated 48 h before challenge and continued for 48 h thereafter protected 80% of the rats against infection. A similar result in rats with established infection was attained with daily doses of 5.0 mg/kg.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6324671      PMCID： PMC185491          DOI： 10.1128/AAC.25.2.281

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.

Authors:  M P Bisschop; J M Merkus; H Scheygrond; J Van Cutsem; A van de Kuy
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1979-08       Impact factor: 2.435

Review 2.  The mechanism of action of the new antimycotic ketoconazole.

Authors:  M Borgers; H Van den Bossche; M De Brabander
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965
  2 in total
  9 in total

1.  Microscopic features of vaginal candidiasis and their relation to symptomatology.

Authors:  C Sonnex; W Lefort
Journal:  Sex Transm Infect       Date:  1999-12       Impact factor: 3.519

2.  Critical role of germ tube formation in the pathogenesis of candidal vaginitis.

Authors:  J D Sobel; G Muller; H R Buckley
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

3.  Isolation of a germ-tube-forming revertant from Candida albicans B311V6.

Authors:  H R Buckley; L Daneo-Moore; J C Ahrens; J D Sobel
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

4.  A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization.

Authors:  Nitin B Dobaria; A C Badhan; R C Mashru
Journal:  AAPS PharmSciTech       Date:  2009-07-24       Impact factor: 3.246

Review 5.  The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases.

Authors:  L Latéy Bradford; Jacques Ravel
Journal:  Virulence       Date:  2016-09-22       Impact factor: 5.882

6.  Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.

Authors:  R Guinet; D Nerson; F de Closets; J Dupouy-Camet; L Kures; M Marjollet; J L Poirot; A Ros; J Texier-Maugein; P J Volle
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

7.  Selection of orally active antifungal agents from 3,5-substituted isoxazolidine derivatives based on acute efficacy-safety profiles.

Authors:  G C Palmer; M J Ordy; R D Simmons; J C Strand; L A Radov; G B Mullen; C R Kinsolving; V St Georgiev; J T Mitchell; S D Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  In Vitro and In Vivo Activities of Essential Oil from the Seed of Anethum graveolens L. against Candida spp.

Authors:  Hong Zeng; Jun Tian; Yuechen Zheng; Xiaoquan Ban; Jingsi Zeng; Yehong Mao; Youwei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-11       Impact factor: 2.629

9.  Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.

Authors:  Per-Anders Mårdh; Jolanta Wågström; Maria Landgren; Jan Holmén
Journal:  Infect Dis Obstet Gynecol       Date:  2004-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.